Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui
Victor Golmer
Jiangsu Hengrui Pharmaceuticals has agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk (NVO) in a deal worth up to $2.6B.
Under the agreement, Novo Nordisk (NVO) will receive exclusive rights to develop, manufacture, and commercialize
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.